New study tracks rare muscle disease without offering treatment

NCT ID NCT05046821

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study follows 150 adults with sporadic inclusion body myositis (sIBM) for two years to see how the disease progresses. Participants visit the clinic every six months for tests like muscle strength, breathing, and swallowing. No treatments are given—the goal is to learn more about the disease to help design future studies.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INCLUSION BODY MYOSITIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Brigham and Women's Hospital

    Boston, Massachusetts, 02115, United States

  • Johns Hopkins University

    Baltimore, Maryland, 21287, United States

  • Kansas University Medical Center

    Fairway, Kansas, 66205, United States

  • Nerve and Muscle Center of Texas

    Houston, Texas, 77030, United States

  • Ohio State University

    Columbus, Ohio, 43221, United States

  • Oregon Health & Science University

    Portland, Oregon, 97239, United States

  • University of California, Irvine

    Orange, California, 92868, United States

  • University of California, Los Angeles

    Los Angeles, California, 90095, United States

  • University of Colorado

    Aurora, Colorado, 80045, United States

  • University of Miami

    Miami, Florida, 33136, United States

  • University of Pennsylvania

    Philadelphia, Pennsylvania, 19104, United States

  • University of Washington

    Seattle, Washington, 98195, United States

  • Washington University in St. Louis

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.